High Expressions of Lgr5 and ALDH1 in Primary Epithelial Ovarian Cancer Correlate with Advanced Tumor Stage and Grade as well as Poor Prognosis of the Patients

Gynecologic and Obstetric Investigation

Volumn 81, Issue 2, 2016, Pages 162-168

  Sun, Yanan ^a   Jia, Xiaopeng ^a   Wu, Xiaohua ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Aldehyde dehydrogenase 1; Cancer stem cell marker; Epithelial ovarian cancer; Leucine rich repeat containing G protein coupled receptor 5; Prognostic relevance

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; G PROTEIN COUPLED RECEPTOR; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLLOID CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84933565305     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000431222     Document Type: Article

References (36)

1. Miow Q, Tan T, Ye J, Lau J, Yokomizo T, Thiery J, Mori S: Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015; 34: 1899-1907.
2. Lynch HT, Casey MJ, Lynch J, White T, Godwin AK: Genetics and ovarian carcinoma. Semin Oncol 1998; 25: 265-280.
3. Naora H: The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 2007; 9: 1-12.
4. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr: Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.
5. Wikborn C, Pettersson F, Moberg P: Delay in diagnosis of epithelial ovarian cancer. Int J Gynaecol Obstet 1996; 52: 263-267.
6. Rufford B, Jacobs I, Menon U: Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 2007; 114: 59-64.
7. Nam J-H, Park J-Y: Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer. Gynecol Obstet Invest 2012; 76: 14-24.
8. Klangsin S, Suntharasaj T, Suwanrath C, Kor-Anantakul O, Prasartwanakit V: Comparison of the five sonographic morphology scoring systems for the diagnosis of malignant ovarian tumors. Gynecol Obstet Invest 2012; 76: 248-253.
9. Perez-Medina T, Orensanz I, Pereira A, Valero de Bernabé J, Engels V, Troyano J, SanFrutos L, Iglesias E: Three-dimensional angioultrasonography for the prediction of malignancy in ovarian masses. Gynecol Obstet Invest 2012; 75: 120-125.
10. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
11. Agarwal R, Kaye S: Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 2005; 16: 4-6.
12. No JH, Moon JM, Kim K, Kim Y-B: Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest 2013; 75: 263-267.
13. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
14. Dyall S, Gayther SA, Dafou D: Cancer stem cells and epithelial ovarian cancer. J Oncol 2010; 2010: 105269.
15. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR: Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011; 16: 368-392.
16. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-2883.
17. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
18. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J: ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009; 22: 817-823.
19. Wang Y-C, Yo Y-T, Lee H-Y, Liao Y-P, Chao T-K, Su P-H, Lai H-C: ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 2012; 180: 1159-1169.
20. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang L-P, Roby KF, Orsulic S: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010; 5:e10277.
21. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9: 3186-3199.
22. Kabulski Z, Frankman O: Histologic malignancy grading in invasive squamous cell carcinoma of the vulva. Int J Gynaecol Obstet 1977; 16: 233-237.
23. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-104.
24. EL-Hadaad HA: Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer. Ann Diagn Pathol 2014; 18: 58-62.
25. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18:S19-S32.
26. Choi J-H, Wong AS, Huang H-F, Leung PC: Gonadotropins and ovarian cancer. Endocr Rev 2007; 28: 440-461.
27. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
28. Adhikari AS, Agarwal N, Iwakuma T: Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci (Landmark Ed) 2010; 16: 1927-1938.
29. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
30. Walker F, Zhang H-H, Odorizzi A, Burgess AW: LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One 2011; 6:e22733.
31. Nakata S, Campos B, Bageritz J, Lorenzo Bermejo J, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P: LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stemlike cells. Brain Pathol 2013; 23: 60-72.
32. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-3389.
33. Deng Y, Zhou J, Fang L, Cai Y, Ke J, Xie X, Huang Y, Huang M, Wang J: ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. Br J Cancer 2014; 110: 430-434.
34. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N, Yasui W: Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012; 62: 112-119.
35. Amsterdam A, Raanan C, Schreiber L, Freyhan O, Schechtman L, Givol D: Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship. Acta Histochem 2013; 115: 330-338.
36. Wu C, Xie Y, Gao F, Wang Y, Guo Y, Tian H, Li Y, Fan W: Lgr5 expression as stem cell marker in human gastric gland and its relatedness with other putative cancer stem cell markers. Gene 2013; 525: 18-25.